You are here

Article Text

Article menu
Download PDFPDF
Unexpected outcome (positive or negative) including adverse drug reactions
CASE REPORT
Adalimumab-induced acute myeloid leukaemia in a patient with Crohn’s disease
  1. Talal Alzahrani1,
  2. Abdulelah Nuqali1,
  3. Nejat Naser1 and
  4. Amar R Jariwala2
  1. 1 Department of Medicine, The George Washington University, Washington, District of Columbia, USA
  2. 2 Department of Pathology, The George Washington University, Washington, District of Columbia, USA
  1. Correspondence to Dr Abdulelah Nuqali, abdulelah.n{at}gmail.com

Abstract

We present a patient with Crohn’s disease under treatment with adalimumab who developed acute myeloid leukaemia (AML) with core-binding factor beta gene rearrangement. This case report emphasises the importance of long-term close follow-up of patients receiving adalimumab because of the increased risk of developing AML and other malignancies.

  • haematology (drugs and medicines)
  • crohn’s disease

http://dx.doi.org/10.1136/bcr-2018-225680

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors TA, AN, NN and ARJ contributed to the writing of the manuscript. ARJ also edited the pathology slides and wrote the description of the figures.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.